Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-722 in Interstitial Cystitis/Bladder Pain Syndrome
NCT04208087Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2020
- Primary completion
- Jan 2021
- Countries
- 1
- Sponsor
- Seikagaku Corporation
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Drugs
- SI-722
- Conditions
- interstitial cystitis (IC)
01
Overview
Phase 2, randomised, double-blind trial in interstitial cystitis (IC) comparing SI-722 with Placebo (2 arms). Primary endpoint: Maximum Plasma Concentration at 4 weeks. Started Mar 2020; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
SI-722
Experimental arm receiving SI-722
Placebo
Control arm receiving Placebo
03
Endpoints
Primary
Maximum Plasma Concentration
Beyond the preview
Go deeper on NCT04208087.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208087.